Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. 

LATEST NEWS
Jun 11, 2021
Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria
May 6, 2021
Modus Therapeutics publishes interim report for Q1
Apr 20, 2021
Notice to Annual General Meeting in Modus Therapeutics Holding AB
OUR INVESTORS